Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Molecular medicine: Precision oncology is not an illusion.

Abrahams E, Eck SL.

Nature. 2016 Nov 17;539(7629):357. doi: 10.1038/539357e. No abstract available.

PMID:
27853199
2.

Opening up to precompetitive collaboration.

Altshuler JS, Balogh E, Barker AD, Eck SL, Friend SH, Ginsburg GS, Herbst RS, Nass SJ, Streeter CM, Wagner JA.

Sci Transl Med. 2010 Oct 6;2(52):52cm26. doi: 10.1126/scitranslmed.3001515.

PMID:
20926831
3.

Biomarker qualification via public-private partnerships.

Eck SL, Paul SM.

Clin Pharmacol Ther. 2010 Jan;87(1):21-3. doi: 10.1038/clpt.2009.193. Review.

PMID:
20019697
4.

Gene Therapy Clinical Studies And The CONSORT Guidelines.

Eck SL.

Hum Gene Ther. 2007 Apr 4. [Epub ahead of print] No abstract available.

PMID:
17518611
5.

A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells.

Gutzmer R, Li W, Sutterwala S, Lemos MP, Elizalde JI, Urtishak SL, Behrens EM, Rivers PM, Schlienger K, Laufer TM, Eck SL, Marks MS.

J Immunol. 2004 Jul 15;173(2):1023-32.

6.

EpCAM: A new therapeutic target for an old cancer antigen.

Armstrong A, Eck SL.

Cancer Biol Ther. 2003 Jul-Aug;2(4):320-6. Review.

PMID:
14508099
7.

Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice.

Gruss CJ, Satyamoorthy K, Berking C, Lininger J, Nesbit M, Schaider H, Liu ZJ, Oka M, Hsu MY, Shirakawa T, Li G, Bogenrieder T, Carmeliet P, El-Deiry WS, Eck SL, Rao JS, Baker AH, Bennet JT, Crombleholme TM, Velazquez O, Karmacharya J, Margolis DJ, Wilson JM, Detmar M, Skobe M, Robbins PD, Buck C, Herlyn M.

J Invest Dermatol. 2003 Apr;120(4):683-92.

8.

Gene therapy for high grade gliomas.

Alavi JB, Eck SL.

Expert Opin Biol Ther. 2001 Mar;1(2):239-52. Review.

PMID:
11727533
9.
10.

Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.

Doolittle ND, Anderson CP, Bleyer WA, Cairncross JG, Cloughesy T, Eck SL, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA.

Neuro Oncol. 2001 Jan;3(1):46-54. doi: 10.1093/neuonc/3.1.46.

11.

Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and.

Hustinx R, Shiue CY, Alavi A, McDonald D, Shiue GG, Zhuang H, Lanuti M, Lambright E, Karp JS, Eck SL.

Eur J Nucl Med. 2001 Jan;28(1):5-12.

PMID:
11202452
12.

Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial.

Eck SL, Alavi JB, Judy K, Phillips P, Alavi A, Hackney D, Cross P, Hughes J, Gao G, Wilson JM, Propert K.

Hum Gene Ther. 2001 Jan 1;12(1):97-113. No abstract available.

PMID:
11177547
14.

The prospects for gene therapy.

Eck SL.

Hosp Pract (1995). 1999 Oct 15;34(11):67-75. Review. No abstract available.

PMID:
10887431
15.

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Brenner M, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, Siegler HF, Barranger JA, Karlsson S, Kohn D, Galpin JE, Raffel C, Hesdorffer C, Ilan J, Cassileth P, O'Shaughnessy J, Kun LE, Das TK, Wong-Staal F, Sobol RE, Haubrich R, Sznol M, Rubin J, Sorcher EJ, Rosenblatt J, Walker R, Brigham K, Vogelzang N, Hersh E, Eck SL.

Hum Gene Ther. 2000 Apr 10;11(6):919-79. No abstract available.

PMID:
10779168
16.

Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes.

Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu MY, Dejesus E, McBrian M, Gupta AR, Eck SL, Herlyn M.

Oncogene. 1999 Nov 11;18(47):6469-76.

17.
18.

Potential applications of PET imaging in developing novel cancer therapies.

Hustinx R, Eck SL, Alavi A.

J Nucl Med. 1999 Jun;40(6):995-1002. Review. No abstract available.

19.

Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factors.

Boxhorn HK, Smith JG, Chang YJ, Guerry D, Lee WM, Rodeck U, Turka LA, Eck SL.

Cancer Immunol Immunother. 1998 Jul;46(5):283-92.

PMID:
9690457
20.

Gene therapy for breast cancer.

Boxhorn HK, Eck SL.

Hematol Oncol Clin North Am. 1998 Jun;12(3):665-75. Review.

PMID:
9684104
21.

Gene therapy for malignant gliomas.

Alavi JB, Eck SL.

Hematol Oncol Clin North Am. 1998 Jun;12(3):617-29. Review.

PMID:
9684101
22.

Future directions for the treatment of colorectal carcinoma.

Eck SL.

Hematol Oncol Clin North Am. 1997 Aug;11(4):795-810. Review.

PMID:
9257156
23.

High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation.

Zeng M, Cerniglia GJ, Eck SL, Stevens CW.

Hum Gene Ther. 1997 Jun 10;8(9):1025-32.

PMID:
9189760
24.

Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response.

Smith JG, Raper SE, Wheeldon EB, Hackney D, Judy K, Wilson JM, Eck SL.

Hum Gene Ther. 1997 May 20;8(8):943-54.

PMID:
9195217
25.

Adenovirus-mediated gene therapy of ovarian cancer in a mouse model.

Behbakht K, Benjamin I, Chiu HC, Eck SL, Van Deerlin PG, Rubin SC, Boyd J.

Am J Obstet Gynecol. 1996 Nov;175(5):1260-5.

PMID:
8942498
26.

Mechanism of the induction of anti-tumor immunity by B7.1 and interleukin-12.

Wysocka M, Coughlin CM, Kurzawa HL, Trinchieri G, Eck SL, Lee WM.

Ann N Y Acad Sci. 1996 Oct 31;795:429-33. No abstract available.

PMID:
8958975
27.

Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.

Eck SL, Alavi JB, Alavi A, Davis A, Hackney D, Judy K, Mollman J, Phillips PC, Wheeldon EB, Wilson JM.

Hum Gene Ther. 1996 Aug 1;7(12):1465-82.

PMID:
8844206
28.

B7-1 and interleukin 12 synergistically induce effective antitumor immunity.

Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL.

Cancer Res. 1995 Nov 1;55(21):4980-7.

29.

Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.

Smythe WR, Hwang HC, Elshami AA, Amin KM, Eck SL, Davidson BL, Wilson JM, Kaiser LR, Albelda SM.

Ann Surg. 1995 Jul;222(1):78-86.

30.

Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system.

Smythe WR, Hwang HC, Amin KM, Eck SL, Davidson BL, Wilson JM, Kaiser LR, Albelda SM.

Cancer Res. 1994 Apr 15;54(8):2055-9.

31.

Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-kappa B in vivo.

Eck SL, Perkins ND, Carr DP, Nabel GJ.

Mol Cell Biol. 1993 Oct;13(10):6530-6.

32.

Angioedema presenting as chronic gastrointestinal symptoms.

Eck SL, Morse JH, Janssen DA, Emerson SG, Markovitz DM.

Am J Gastroenterol. 1993 Mar;88(3):436-9.

33.
34.

Antisense oligonucleotides for therapeutic intervention.

Eck SL, Nabel GJ.

Curr Opin Biotechnol. 1991 Dec;2(6):897-904. Review.

PMID:
1367966

Supplemental Content

Support Center